2014/2015 KAN-CCMVV1479U Pharmaceutical Marketing Management
English Title | |
Pharmaceutical Marketing Management |
Course information |
|
Language | English |
Course ECTS | 7.5 ECTS |
Type | Elective |
Level | Full Degree Master |
Duration | One Quarter |
Course period | Autumn, First Quarter |
Timetable | Course schedule will be posted at calendar.cbs.dk |
Study board |
Study Board for MSc in Economics and Business
Administration
|
Course coordinator | |
|
|
The course is organized and taught by Senior Executives from the Health Care industry and companies such as Coloplast, Novo Nordisk, Leo Pharma and Lundbeck | |
Main academic disciplines | |
|
|
Last updated on 10-04-2014 |
Learning objectives | ||||||||||||||||||||||||
At the end of the course the student should be
able to:
• Describe, classify, structure and combine concepts, theories, methods and models taught • Identify and develop relevant issues within pharmaceutical marketing • Analyze and synthesize specific issues within pharmaceutical marketing by using the concepts, theories, methods and models taught • Assess and communicate problem-solving on a reflective, scientific basis |
||||||||||||||||||||||||
Course prerequisites | ||||||||||||||||||||||||
It is recommended that students have a basic
knowledge of theories about consumer behaviour and marketing
(bachelor level). The course is especially relevant for graduate
students from e.g. the EMF, BCM and IMM lines at CBS or students
from other lines wanting to expand their marketing skills. All
students are welcome to attend.
This course is strongly recommended for students planning careers in biotechnology, pharmaceuticals, other R&D-heavy industries, management consulting etc. |
||||||||||||||||||||||||
Examination | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
Course content and structure | ||||||||||||||||||||||||
The course will give an overview of the
pharmaceutical industry and how marketing has become essential even
for one of the most R&D-heavy industries.Many people –
also within the pharmaceutical companies themselves - find
marketing circumspect and believe pharmaceuticals should be sold on
scientific merits only. However, R&D productivity has fallen
and companies need to maximize return on each and every innovation
just to survive. Therefore, the pharmaceutical industry is a good
place to learn about recurrent as well as future challenges for
marketeers, e.g:
The course will introduce participants to the fundamentals of pharmaceutical marketing management, including for example:
|
||||||||||||||||||||||||
Teaching methods | ||||||||||||||||||||||||
Lectures and case work | ||||||||||||||||||||||||
Further Information | ||||||||||||||||||||||||
Changes in course schedule may occur
Friday 08.00-10.30, week 36-42 Friday 08.00-12.35, week 43 |
||||||||||||||||||||||||
Expected literature | ||||||||||||||||||||||||
1. Schacter,
Bernice Zeldin (2006). The New Medicines: How Drugs are
Created, Approved, Marketed and Sold. Westport, Conneticut:
Praeger Publishers. ISBN 0-275-98141-X Chapter 1, Chapter 3-11
2. Deutsche Bank: Pharmaceutical Industry R&D Pipeline, January 2012 3. Pharma Product Launches: Strategies for success, A FirstWord ExpertViews Report, October 2011 4. Keller, Kevin Lane (2008, 3. ed), Strategic Brand Management, chapter 2-3 5. Denend, Lyn, Zenios, Stefanos and Chess, Robert (2005). Abbott Laboratories and Humira: Launching a Blockbuster Drug. Stanford, California: Stanford Graduate School of Business. Case OIT-44 6. Achieving Global Launch Excellence, IMS Special Report, January 2009 7. Ellery T. & Hansen N.. Pharmaceutical Lifecycle Management; Making the Most out of Each and Every Brand. Wiley. 2012. Part D and Part E: page 113-206 8. Fereshteh Barei, PhD, et al (2013): The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation. Generics and Biosimilars Initiative Journal, Volume 2, Issue 1. 9. PriceWaterhouseCoopers. Pharma 2020: Challenging Business Models. Which path will you take? 10. Article: Navigating a changing health care environment, July 2012 McKinsey & Company 11. Article: Jose Santos et al. Towards a Theory of Business Model Innovation within Incumbent Firms. Page 1-47. INSEAD Faculty Working Paper, March 2009 12. KPMG (2011). Key Challenges facing the Pharmaceutical Industry. 13. A Wake-up call for big Pharma, McKinsey Quarterly, 2011 |
Last updated on
10-04-2014